The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | MRD by mass spectrometry in PB and NGS in BM in patients with multiple myeloma treated with Dara-KRd
Benjamin Derman, MD, The University of Chicago, Chicago, IL, shares the results of a study evaluating the concordance of measurable residual disease (MRD) by next-generation sequencing (NGS) in bone marrow (BM) and mass spectrometry (MS) in peripheral blood (PB) using EXENT and liquid chromatography-mass spectrometry (LC-MS) in patients with multiple myeloma treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) without autologous hematopoietic stem cell transplant (autoHSCT). Overall, the study found that the two MRD assessment techniques may be complementary, and reported that MS positivity may represent false positives due to immunoglobulin recycling. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Honoraria for advisory board fees from Janssen, Sanofi, and COTA healthcare.
